Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer

News — By on November 24, 2008 at 9:00 am

Genentech, Inc. (NYSE:DNA) today announced that a Phase III study (RIBBON 1) of Avastin® (bevacizumab), in combination with taxane, anthracycline-based or capecitabine chemotherapies for first-line treatment of metastatic HER2-negative breast cancer, met its primary endpoint of increasing the time patients lived without their disease advancing, compared to the chemotherapies alone.

Please read the complete article and let us know what you think below.

Leave a Reply


Leave a Trackback